vs
CITIZENS FINANCIAL SERVICES INC（CZFS）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是CITIZENS FINANCIAL SERVICES INC的1.2倍（$35.5M vs $29.6M），CITIZENS FINANCIAL SERVICES INC净利率更高（35.4% vs -304.2%，领先339.6%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 13.0%），CITIZENS FINANCIAL SERVICES INC自由现金流更多（$35.2M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 6.9%）
公民金融集团是一家美国银行控股公司，总部位于罗得岛州普罗维登斯。集团旗下拥有公民银行（Citizens Bank, N.A.），业务覆盖美国康涅狄格、特拉华、佛罗里达等十余个州及华盛顿哥伦比亚特区。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
CZFS vs RXRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $29.6M | $35.5M |
| 净利润 | $10.5M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 44.2% | -304.8% |
| 净利率 | 35.4% | -304.2% |
| 营收同比 | 13.0% | 681.7% |
| 净利润同比 | 31.3% | 39.6% |
| 每股收益（稀释后） | $2.17 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $29.6M | $35.5M | ||
| Q3 25 | $29.0M | $5.2M | ||
| Q2 25 | $27.3M | $19.2M | ||
| Q1 25 | $26.4M | $14.7M | ||
| Q4 24 | $26.2M | $4.5M | ||
| Q3 24 | $25.1M | $26.1M | ||
| Q2 24 | $24.6M | $14.4M | ||
| Q1 24 | $25.9M | $13.8M |
| Q4 25 | $10.5M | $-108.1M | ||
| Q3 25 | $10.0M | $-162.3M | ||
| Q2 25 | $8.5M | $-171.9M | ||
| Q1 25 | $7.6M | $-202.5M | ||
| Q4 24 | $8.0M | $-178.9M | ||
| Q3 24 | $7.5M | $-95.8M | ||
| Q2 24 | $5.3M | $-97.5M | ||
| Q1 24 | $7.0M | $-91.4M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
| Q4 25 | 44.2% | -304.8% | ||
| Q3 25 | 42.6% | -3327.6% | ||
| Q2 25 | 38.1% | -916.8% | ||
| Q1 25 | 35.5% | -1297.9% | ||
| Q4 24 | 37.2% | -4042.4% | ||
| Q3 24 | 36.9% | -377.1% | ||
| Q2 24 | 25.9% | -697.4% | ||
| Q1 24 | 32.8% | -698.4% |
| Q4 25 | 35.4% | -304.2% | ||
| Q3 25 | 34.5% | -3135.3% | ||
| Q2 25 | 31.0% | -894.2% | ||
| Q1 25 | 28.8% | -1373.3% | ||
| Q4 24 | 30.5% | -3935.5% | ||
| Q3 24 | 30.0% | -367.5% | ||
| Q2 24 | 21.4% | -676.6% | ||
| Q1 24 | 27.1% | -662.4% |
| Q4 25 | $2.17 | $-0.17 | ||
| Q3 25 | $2.09 | $-0.36 | ||
| Q2 25 | $1.76 | $-0.41 | ||
| Q1 25 | $1.60 | $-0.50 | ||
| Q4 24 | $1.64 | $-0.56 | ||
| Q3 24 | $1.57 | $-0.34 | ||
| Q2 24 | $1.10 | $-0.40 | ||
| Q1 24 | $1.48 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $34.3M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $338.1M | $1.1B |
| 总资产 | $3.1B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | $34.3M | $743.3M | ||
| Q3 25 | $31.1M | $659.8M | ||
| Q2 25 | $49.5M | $525.1M | ||
| Q1 25 | $36.8M | $500.5M | ||
| Q4 24 | $42.2M | $594.4M | ||
| Q3 24 | $36.8M | $427.6M | ||
| Q2 24 | $38.4M | $474.3M | ||
| Q1 24 | $29.6M | $296.3M |
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
| Q4 25 | $338.1M | $1.1B | ||
| Q3 25 | $327.7M | $1.0B | ||
| Q2 25 | $313.7M | $919.1M | ||
| Q1 25 | $308.3M | $933.9M | ||
| Q4 24 | $299.7M | $1.0B | ||
| Q3 24 | $298.7M | $524.6M | ||
| Q2 24 | $286.5M | $584.4M | ||
| Q1 24 | $282.7M | $401.2M |
| Q4 25 | $3.1B | $1.5B | ||
| Q3 25 | $3.1B | $1.4B | ||
| Q2 25 | $3.0B | $1.3B | ||
| Q1 25 | $3.0B | $1.3B | ||
| Q4 24 | $3.0B | $1.4B | ||
| Q3 24 | $3.0B | $726.5M | ||
| Q2 24 | $2.9B | $775.9M | ||
| Q1 24 | $2.9B | $557.8M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $36.5M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $35.2M | $-47.3M |
| 自由现金流率自由现金流/营收 | 119.0% | -133.1% |
| 资本支出强度资本支出/营收 | 4.4% | 3.5% |
| 现金转化率经营现金流/净利润 | 3.49× | — |
| 过去12个月自由现金流最近4个季度 | $53.8M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $36.5M | $-46.1M | ||
| Q3 25 | $2.9M | $-117.4M | ||
| Q2 25 | $6.0M | $-76.4M | ||
| Q1 25 | $10.9M | $-132.0M | ||
| Q4 24 | $33.2M | $-115.4M | ||
| Q3 24 | $6.2M | $-59.2M | ||
| Q2 24 | $3.0M | $-82.2M | ||
| Q1 24 | $13.5M | $-102.3M |
| Q4 25 | $35.2M | $-47.3M | ||
| Q3 25 | $2.7M | $-117.6M | ||
| Q2 25 | $5.5M | $-79.6M | ||
| Q1 25 | $10.4M | $-133.8M | ||
| Q4 24 | $31.9M | $-116.7M | ||
| Q3 24 | $5.6M | $-63.8M | ||
| Q2 24 | $2.9M | $-83.4M | ||
| Q1 24 | $13.4M | $-109.0M |
| Q4 25 | 119.0% | -133.1% | ||
| Q3 25 | 9.4% | -2272.5% | ||
| Q2 25 | 20.1% | -413.9% | ||
| Q1 25 | 39.2% | -907.4% | ||
| Q4 24 | 121.6% | -2567.7% | ||
| Q3 24 | 22.3% | -244.6% | ||
| Q2 24 | 11.8% | -578.5% | ||
| Q1 24 | 51.5% | -789.9% |
| Q4 25 | 4.4% | 3.5% | ||
| Q3 25 | 0.5% | 4.7% | ||
| Q2 25 | 1.8% | 16.4% | ||
| Q1 25 | 2.2% | 12.4% | ||
| Q4 24 | 5.0% | 28.6% | ||
| Q3 24 | 2.5% | 17.5% | ||
| Q2 24 | 0.5% | 8.2% | ||
| Q1 24 | 0.4% | 48.2% |
| Q4 25 | 3.49× | — | ||
| Q3 25 | 0.29× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | 1.44× | — | ||
| Q4 24 | 4.16× | — | ||
| Q3 24 | 0.83× | — | ||
| Q2 24 | 0.57× | — | ||
| Q1 24 | 1.92× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
